AXDX vs. HLTH, TLIS, TBIO, PRPO, OMIC, RPID, BNGO, KALA, BIVI, and ATIP
Should you be buying Accelerate Diagnostics stock or one of its competitors? The main competitors of Accelerate Diagnostics include Cue Health (HLTH), Talis Biomedical (TLIS), Telesis Bio (TBIO), Precipio (PRPO), Singular Genomics Systems (OMIC), Rapid Micro Biosystems (RPID), Bionano Genomics (BNGO), KALA BIO (KALA), BioVie (BIVI), and ATI Physical Therapy (ATIP). These companies are all part of the "medical" sector.
Cue Health (NASDAQ:HLTH) and Accelerate Diagnostics (NASDAQ:AXDX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends, community ranking, profitability and media sentiment.
Accelerate Diagnostics has lower revenue, but higher earnings than Cue Health. Accelerate Diagnostics is trading at a lower price-to-earnings ratio than Cue Health, indicating that it is currently the more affordable of the two stocks.
45.5% of Cue Health shares are held by institutional investors. Comparatively, 17.1% of Accelerate Diagnostics shares are held by institutional investors. 12.5% of Cue Health shares are held by insiders. Comparatively, 43.6% of Accelerate Diagnostics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Accelerate Diagnostics has a net margin of -454.95% compared to Accelerate Diagnostics' net margin of -526.48%. Cue Health's return on equity of 0.00% beat Accelerate Diagnostics' return on equity.
In the previous week, Accelerate Diagnostics had 11 more articles in the media than Cue Health. MarketBeat recorded 11 mentions for Accelerate Diagnostics and 0 mentions for Cue Health. Cue Health's average media sentiment score of -0.51 beat Accelerate Diagnostics' score of -0.59 indicating that Accelerate Diagnostics is being referred to more favorably in the news media.
Accelerate Diagnostics received 353 more outperform votes than Cue Health when rated by MarketBeat users. Likewise, 63.44% of users gave Accelerate Diagnostics an outperform vote while only 7.14% of users gave Cue Health an outperform vote.
Cue Health has a beta of 1.3, suggesting that its share price is 30% more volatile than the S&P 500. Comparatively, Accelerate Diagnostics has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500.
Cue Health presently has a consensus price target of $3.00, suggesting a potential upside of 2,207.69%. Accelerate Diagnostics has a consensus price target of $1.00, suggesting a potential upside of 11.73%. Given Accelerate Diagnostics' higher probable upside, analysts plainly believe Cue Health is more favorable than Accelerate Diagnostics.
Summary
Accelerate Diagnostics beats Cue Health on 11 of the 18 factors compared between the two stocks.
Get Accelerate Diagnostics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AXDX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AXDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Accelerate Diagnostics Competitors List
Related Companies and Tools
